Published in Regul Toxicol Pharmacol on February 01, 2010
The human early-life exposome (HELIX): project rationale and design. Environ Health Perspect (2014) 1.44
A population model of integrative cardiovascular physiology. PLoS One (2013) 0.81
Linking fate model in freshwater and PBPK model to assess human internal dosimetry of B(a)P associated with drinking water. Environ Geochem Health (2011) 0.77
Studying permethrin exposure in flight attendants using a physiologically based pharmacokinetic model. J Expo Sci Environ Epidemiol (2013) 0.76
Physiologically based pharmacokinetic models: integration of in silico approaches with micro cell culture analogues. Curr Drug Metab (2012) 0.76
A probabilistic model of human variability in physiology for future application to dose reconstruction and QIVIVE. Front Pharmacol (2015) 0.75
Development of a physiologically based kinetic model for 99m-technetium-labelled carbon nanoparticles inhaled by humans. Inhal Toxicol (2009) 0.96
Use of historical control data for assessing treatment effects in clinical trials. Pharm Stat (2013) 0.95
Fusarium head blight and associated mycotoxin occurrence on winter wheat in Luxembourg in 2007/2008. Food Addit Contam Part A Chem Anal Control Expo Risk Assess (2010) 0.91
Improvement of HepG2/C3a cell functions in a microfluidic biochip. Biotechnol Bioeng (2011) 0.90
Ventilatory response to a hyperoxic test is related to the frequency of short apneic episodes in late preterm neonates. Pediatr Res (2007) 0.89
Metabolomics-on-a-chip and predictive systems toxicology in microfluidic bioartificial organs. Anal Chem (2012) 0.87
Physiologically-based Kinetic Modelling (PBK Modelling): meeting the 3Rs agenda. The report and recommendations of ECVAM Workshop 63. Altern Lab Anim (2007) 0.84
A physiologically based toxicokinetic model for the zebrafish Danio rerio. Environ Sci Technol (2013) 0.84
Toxicokinetics of inhaled trichloroethylene and tetrachloroethylene in humans at 1 ppm: empirical results and comparisons with previous studies. Toxicol Sci (2006) 0.84
Metabolomics-on-a-chip and metabolic flux analysis for label-free modeling of the internal metabolism of HepG2/C3A cells. Mol Biosyst (2012) 0.83
Investigation of ifosfamide nephrotoxicity induced in a liver-kidney co-culture biochip. Biotechnol Bioeng (2012) 0.83
Mirror syndrome due to parvovirus B19 hydrops complicated by severe maternal pulmonary effusion. Prenat Diagn (2006) 0.81
Prediction of dose-hepatotoxic response in humans based on toxicokinetic/toxicodynamic modeling with or without in vivo data: a case study with acetaminophen. Toxicol Lett (2013) 0.80
A cocktail of metabolic probes demonstrates the relevance of primary human hepatocyte cultures in a microfluidic biochip for pharmaceutical drug screening. Int J Pharm (2011) 0.79
Kinetic modelling of in vitro cell-based assays to characterize non-specific bindings and ADME processes in a static and a perfused fluidic system. Toxicol Lett (2011) 0.79
Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol (2011) 0.78
Metabolomics-on-a-chip of hepatotoxicity induced by anticancer drug flutamide and Its active metabolite hydroxyflutamide using HepG2/C3a microfluidic biochips. Toxicol Sci (2012) 0.78
Interpreting PCB levels in breast milk using a physiologically based pharmacokinetic model to reconstruct the dynamic exposure of Italian women. J Expo Sci Environ Epidemiol (2012) 0.78
Evaluation of seven drug metabolisms and clearances by cryopreserved human primary hepatocytes cultivated in microfluidic biochips. Xenobiotica (2012) 0.77
Quantifying heterogeneity in exposure-risk relationships using exhaled breath biomarkers for 1,3-butadiene exposures. J Breath Res (2008) 0.75
Predicting in vivo gene expression in macrophages after exposure to benzo(a)pyrene based on in vitro assays and toxicokinetic/toxicodynamic models. Toxicol Lett (2010) 0.75